CN111686116B - 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用 - Google Patents
孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用 Download PDFInfo
- Publication number
- CN111686116B CN111686116B CN202010511997.2A CN202010511997A CN111686116B CN 111686116 B CN111686116 B CN 111686116B CN 202010511997 A CN202010511997 A CN 202010511997A CN 111686116 B CN111686116 B CN 111686116B
- Authority
- CN
- China
- Prior art keywords
- osteoporosis
- pregnane
- pregnane derivative
- osteoclast
- osteoclast differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010511997.2A CN111686116B (zh) | 2020-06-08 | 2020-06-08 | 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010511997.2A CN111686116B (zh) | 2020-06-08 | 2020-06-08 | 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111686116A CN111686116A (zh) | 2020-09-22 |
CN111686116B true CN111686116B (zh) | 2021-05-04 |
Family
ID=72479668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010511997.2A Active CN111686116B (zh) | 2020-06-08 | 2020-06-08 | 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111686116B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001008677A1 (en) * | 1999-07-28 | 2001-02-08 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
CN106902124A (zh) * | 2017-01-18 | 2017-06-30 | 南京大学 | 齐墩果酸类衍生物的应用 |
-
2020
- 2020-06-08 CN CN202010511997.2A patent/CN111686116B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001008677A1 (en) * | 1999-07-28 | 2001-02-08 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
CN106902124A (zh) * | 2017-01-18 | 2017-06-30 | 南京大学 | 齐墩果酸类衍生物的应用 |
Non-Patent Citations (6)
Title |
---|
Inhibitors of multidrug efflux pumps of Pseudomonas aeruginosa from natural sources: An in silico high-throughput virtual screening and in vitro validation;Gianmarco Mangiaterra 等;《Med Chem Res》;20161219;第26卷;第414-430页 * |
Novel heterocyclic ring-fused oleanolic acid derivatives as osteoclast inhibitors for osteoporosis;Jing Wu 等;《Med. Chem. Commun.》;20161231;第7卷;第371-377页 * |
Novel oxysterols activate the Hedgehog pathway and induce osteogenesis;Frank Stappenbeck 等;《Bioorganic & Medicinal Chemistry Letters》;20120727;第22卷;第5893-5897页 * |
Synthesis and biological evaluation of heterocyclic analogues of pregnenolone as novel anti-osteoporotic agents;Saransh Wales Maurya 等;《Bioorganic & Medicinal Chemistry Letters》;20170204;第27卷;第1390-1396页 * |
中药防治类风湿关节炎骨破坏的研究进展;王钢 等;《中国骨质疏松杂志》;20170731;第23卷(第7期);第963-968页 * |
黑骨藤抑制破骨细胞分化及骨吸收能力的活性部位研究;甄茹 等;《中国实验方剂学杂志》;20150131;第21卷(第1期);第112-116页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111686116A (zh) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytes | |
Tao et al. | Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-κB activated pyroptosis pathways | |
Idris et al. | The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo | |
Wei et al. | Alpinetin ameliorates bone loss in LPS-induced inflammation osteolysis via ROS mediated P38/PI3K signaling pathway | |
Song et al. | Nuciferine prevents bone loss by disrupting multinucleated osteoclast formation and promoting type H vessel formation | |
Zhang et al. | Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling | |
Zhang et al. | Flufenamic acid inhibits osteoclast formation and bone resorption and act against estrogen-dependent bone loss in mice | |
Xu et al. | Bisphosphonate‐enoxacin inhibit osteoclast formation and function by abrogating RANKL‐induced JNK signalling pathways during osteoporosis treatment | |
Yang et al. | Scutellarin ameliorates osteoarthritis by protecting chondrocytes and subchondral bone microstructure by inactivating NF-κB/MAPK signal transduction | |
Zeng et al. | Alpinetin alleviates osteoporosis by promoting osteogenic differentiation in BMSCs by triggering autophagy via PKA/mTOR/ULK1 signaling | |
Huo et al. | p300/CBP inhibitor A-485 inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss | |
JP2010509247A (ja) | Acat阻害剤及び線維症の予防又は治療におけるその使用 | |
Qiu et al. | Neratinib exerts dual effects on cartilage degradation and osteoclast production in Osteoarthritis by inhibiting the activation of the MAPK/NF-κB signaling pathways | |
CN111686116B (zh) | 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用 | |
Ma et al. | Neutralization of interleukin-11 attenuates silica particles-induced pulmonary inflammation and fibrosis in vivo | |
Wang et al. | Phenobarbital inhibits osteoclast differentiation and function through NF-κB and MAPKs signaling pathway | |
CN111494374B (zh) | 香草木宁碱在制备破骨细胞分化抑制剂中的应用 | |
Guo et al. | Probucol suppresses osteoclastogenesis via activating Nrf2 signaling and ameliorates ovariectomy-induced bone loss | |
CN111658649B (zh) | 生物碱在制备破骨细胞分化抑制剂中的应用 | |
Cao et al. | Anemoside B4 attenuates RANKL-induced osteoclastogenesis by upregulating Nrf2 and dampens ovariectomy-induced bone loss | |
Lei et al. | Pulsed electromagnetic fields inhibit osteoclast differentiation in RAW264. 7 macrophages via suppression of the protein kinase B/mammalian target of rapamycin signaling pathway | |
KR102414285B1 (ko) | 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물 | |
EP3378490B1 (en) | Ectopic ossification treatment drug having mechanism for blocking par1 | |
CN114191450B (zh) | 普鲁士蓝及其类似物在制备预防、延缓或治疗骨质疏松症药物中的应用 | |
CN113616631B (zh) | Dusp6抑制剂bci在制备骨质疏松药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee after: Institute of Microbiology, Guangdong Academy of Sciences Patentee after: SUN YAT-SEN University Address before: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee before: GUANGDONG INSTITUTE OF MICROBIOLOGY (GUANGDONG DETECTION CENTER OF MICROBIOLOGY) Patentee before: SUN YAT-SEN University |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221018 Address after: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee after: Institute of Microbiology, Guangdong Academy of Sciences Address before: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee before: Institute of Microbiology, Guangdong Academy of Sciences Patentee before: SUN YAT-SEN University |
|
TR01 | Transfer of patent right |